Federal Register Notices

View Federal Register notices of proposed exclusive licenses. Clicking on the "View" links will display the Federal Register Notice in a new tab. You can also search directly on the Federal Register site.

View Date Published Title Comments Close On Dates
View Government-Owned Inventions; Availability for Licensing
View Prospective Grant of Exclusive License: Human Monoclonal Antibodies, Their Fragments and Derivatives as Biotherapeutics for the Treatment of HIV Infections Only written comments and/or application for a license, which are received by the NIH Office of Technology Transfer on or before August 1, 2006 will be considered.
View Government-Owned Inventions; Availability for Licensing
View Government-Owned Inventions; Availability for Licensing
View Government-Owned Inventions; Availability for Licensing
View Prospective Grant of Exclusive License: The Development of C-6 and C-8 Modified cAMP-Derivatives for the Treatment of Cancer Only written comments and/or applications for a license which are received by the NIH Office of Technology Transfer on or before July 17, 2006 will be considered.
View Government-Owned Inventions; Availability for Licensing
View Prospective Grant of Exclusive License: The Development of C-6 and C-8 Modified cAMP-Derivatives for the Treatment of Cancer Only written comments and/or applications for a license which are received by the NIH Office of Technology Transfer on or before June 10, 2006 will be considered.
View Government-Owned Inventions; Availability for Licensing
View Government-Owned Inventions; Availability for Licensing
View Government-Owned Inventions; Availability for Licensing
View Prospective Grant of Exclusive License: Use of Single Chain T-Cell Receptors To Diagnose and Treat Cancer Only written comments and/or applications for a license which are received by the NIH Office of Technology Transfer on or before June 13, 2006 will be considered.
View Prospective Grant of an Exclusive License: Therapeutics for the Treatment of Neurodegenerative Disorders Only written comments and/or license applications which are received by the National Institutes of Health on or before June 13, 2006 will be considered.
View Annual Comprehensive List of Guidance Documents at the Food and Drug Administration We welcome general comments on this list and on agency guidance documents at any time.
View Prospective Grant of Exclusive License: The Use of IL13-PE38 for the Treatment of Asthma and Pulmonary Fibrosis Only written comments and/or applications for a license which are received by the NIH Office of Technology Transfer on or before May 22, 2006 will be considered.
View Government-Owned Inventions; Availability for Licensing
View Prospective Grant of Exclusive License: The Use of HMG-CoA Inhibitors for the Treatment of Adenocarcinomas and Ewing's Sarcoma Only written comments and/or applications for a license which are received by the NIH Office of Technology Transfer on or before May 22, 2006 will be considered.
View Prospective Grant of Exclusive License: Dengue Virus Vaccine N/A
View Prospective Grant of Exclusive License: The Use of IL13-PE38 for the Treatment of Asthma and Pulmonary Fibrosis
View Prospective Grant of Exclusive License: Device for Cell Culturing, Monitoring and Containment Only written comments and/or applications for a license received by the NIH Office of Technology Transfer on or before April 24, 2006 will be considered.
View Prospective Grant of Exclusive License: Aminoflavone Compounds as Anti-Cancer Agents Only written comments and/or license applications which are received by the National Institutes of Health on or before April 10, 2006 will be considered.
View Prospective Grant of Exclusive License: Food Quality Indicator Device Only written comments and/or application for a license which are received by the National Institutes of Health on or before April 10, 2006 will be considered.
View Prospective Grant of an Exclusive License: “Vasostatin as Marrow Protectant” and “Use of Calreticulin and Calreticulin Fragments To Inhibit Endothelial Cell Growth and Angiogenesis and Suppress Tumor Growth” Only written comments and/or license applications which are received by the National Institutes of Health on or before April 3, 2006 will be considered.
View Prospective Grant of Exclusive License: FDA Approvable Human DNA Diagnostic Test for Endometriosis Only written comments and/or application for a license which are received by the National Institutes of Health on or before April 3, 2006 will be considered.
View Prospective Grant of Exclusive License: FDA Approvable Human Diagnostic for Osteoarthritis Only written comments and/or application for a license which is received by the NIH Office of Technology Transfer on or before March 21, 2006 will be considered.